MedPath

Clinical study to find the effectiveness of Meniphib tablets in female patients suffering from premenstrual syndrome.

Phase 3
Completed
Conditions
Health Condition 1: N00-N99- Diseases of the genitourinary system
Registration Number
CTRI/2021/02/031249
Lead Sponsor
Bhargava Phytolab
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
100
Inclusion Criteria

1)Subject is willing and able to give written informed consent

2)Female subjects aged � 18 and � 45 years not attained menopause

3)Subject having clinical diagnosis as per investigators judgment for Premenstrual Syndrome

4)Subjects of childbearing potential should have a negative pregnancy test at Screening

5)Female subjects of childbearing potential should be willing to practice appropriate birth control during the entire duration of the study

Appropriate birth control is defined in the study as any medically recommended method (or combination of methods) except oral birth control pills as per standard of care

6)Subject is willing, able and likely to comply with all study procedures and restrictions

Exclusion Criteria

1)Subject is pregnant or breast-feeding at the time of screening, or planning

to be pregnant during the study

2)History of current or past Psychiatric Disorders

3)History consistent with endometriosis

4)Diagnosis of ill-defined, obscure pelvic lesions, particularly, undiagnosed ovarian enlargement, hepatic disease as manifested by medical history

5)History of mammary carcinoma

6)History of pulmonary embolism or phlebothrombosis

7)Undiagnosed vaginal bleeding

8)Subject suffering from porphyria

9)Subject suffering from uncontrolled diabetes mellitus

10)History of malignant melanoma

11)Subject suffering from cholecystitis or pancreatitis

12)Cardiovascular or renal disease

13)Subject taking birth control pills will be excluded from the study.

14)Subject taking diuretics prostaglandin inhibitors or pyridoxine (putative treatments for MRMD) will similarly be excluded from the study

15)Subject taking psychotropic agents

16)Subjects who had an administration of other investigational product or medical device for clinical trial 4 weeks prior to participation of clinical trial

17)Any other condition that in the investigators judgment might interfere with study objectives

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath